WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
NEWARK, Calif., Feb. 03, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the following healthcare conferences during the month of February.
LEERINK Partners 5th Annual Global Healthcare Conference
Date: Wednesday, February 10, 2016
Time: 11:55 a.m. EST
Location: New York, New York
2016 RBC Capital Markets’ Global Healthcare Conference
Date: Wednesday, February 24, 2016
Time: 11:00 a.m. EST
Location: New York, New York
These presentations will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
